2025 Park City Myeloma & Lymphoma Summit

08:15 AM - 08:25 AM

Introductions – Douglas W Sborov, MD

08:25 AM - 08:45 AM

CAR-T in Perspective: Role of CAR-T in the RRMM Setting – Lekha Mikkilineni, MD

08:45 AM - 09:05 AM

Bispecific T-cell Engagers: Standard of care, Combination Regimens, and the Future – Amandeep Godara, MBBS

09:05 AM - 09:25 AM

Drug Sequencing: The Value of Real-World Data – Doris Hansen, MD

09:25 AM - 09:35 AM

Data in Perspective: Where We Are and Where We Are Going – Lekha Mikkilineni, MD

09:35 AM - 09:55 AM

Panel Q&A/Debate – Lekha Mikkilineni, MD; Amandeep Godara, MBBS; Doris Hansen, MD; Douglas W Sborov, MD

10:10 AM - 10:40 AM

Standard of Care and Unmet Needs in First-Line Treatment in 2025 – Andrew Yee, MD

10:40 AM - 11:05 AM

Transplant and Maintenance in the Modern Era – Craig Hofmeister, MD, MPH

11:05 AM - 11:15 AM

Data in Perspective: Future of Upfront Treatment for NDMM – Amandeep Godara, MBBS

11:15 AM - 11:30 AM

Panel Q&A/Debate – Andrew Yee, MD; Craig Hofmeister, MD, MPH; Amandeep Godara, MBBS; Douglas W Sborov, MD

11:30 AM - 11:40 AM

"Down with Dex" in Myeloma Therapy – Benjamin Solomon, MD

11:40 AM - 11:50 AM

Successful Implementation of a Community-Based Bispecific Program – Wayne Ormsby, MD

11:50 AM - 12:05 PM

Mitigation Strategies for CAR-T and Bispecific-Associated Toxicities – Samuel Shewan, PA-C

12:05 PM - 12:20 PM

Panel Q&A/Debate – Benjamin Solomon, MD; Wayne Ormsby, MD; Samuel Shewan, PA-C; Xylina Gregg, MD

01:20 PM - 01:40 PM

DLBCL in 2025 - Role of MRD in response assessment and surveillance, new treatment options for r/r DLBCL (transplant-ineligible options + CAR T/BsAbs), role of CNS prophylaxis – Richard T. Maziarz, MD

01:40 PM - 01:50 PM

Debate 1: Is there still a role for CNS prophylaxis in DLBCL? – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD

01:50 PM - 02:00 PM

Debate 2: Best 2L + option for transplant ineligible LBCL patients — bispecific + GemOx (STARGLO, EPCORE NHL-2) vs. Mosun+Pola (SUNMO trial) – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD

02:00 PM - 02:10 PM

What's in the Pipeline? New Drugs on the Horizon for Lymphoma – Justin Call, MD

02:10 PM - 02:20 PM

Data in Perspective: DLBCL – Belisario Arango, MD

02:20 PM - 02:35 PM

Q&A – Narendranath Epperla, MD; Hua-Jay "Jeff" J Cherng, MD; Justin Call, MD; Belisario Arango, MD; Bradley Hunter, MD

02:55 PM - 03:20 PM

CLL in 2025 - touching on MRD, doublet/triplet regimens – Stephen Spurgeon, MD

03:20 PM - 03:30 PM

Debate 1: Is fixed-duration doublet or triplet therapy the future for untreated CLL? (Acalabrutinib, venetoclax +/- obinutuzumab - AMPLIFY; Sonrotoclax + Zanubrutinib - MAJIC, etc) – Matthew Mei, MD; Victoria Vardell, MD

03:30 PM - 03:40 PM

Debate 2: What is the best treatment for TP53-mutated CLL - BTKi or venetoclax-based? – Daniel Arthur Ermann, MD; Matthew Mei, MD

03:40 PM - 03:55 PM

Q&A – Stephen Spurgeon, MD; Matthew Mei, MD; Daniel Arthur Ermann, MD; Victoria Vardell, MD; Lindsey Fitzgerald, MD, PhD